tiprankstipranks
Insulet (CH:GOV)
:GOV
Switzerland Market

Insulet (GOV) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

GOV Analyst Ratings

Strong Buy
21Ratings
Strong Buy
17 Buy
3 Hold
1 Sell
Based on 21 analysts giving stock ratings to
Insulet
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GOV Stock 12 Month Forecast

Average Price Target

Based on 21 Wall Street analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is CHF181.71 with a high forecast of CHF239.61 and a low forecast of CHF140.18. The average price target represents a change from the last price of .
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
Highest Price TargetCHF239.61Average Price TargetCHF181.71Lowest Price TargetCHF140.18
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
CHF141.81
Hold
Downgraded
07/28/26
Insulet assumed with Neutral from Buy at UBSInsulet assumed with Neutral from Buy at UBS
Truist Financial Analyst forecast on CH:GOV
Truist Financial
Truist Financial
CHF178.49CHF171.15
Buy
Reiterated
07/13/26
Insulet price target lowered to $210 from $219 at TruistInsulet price target lowered to $210 from $219 at Truist
RBC Capital
CHF228.2CHF199.68
Buy
Reiterated
07/13/26
Insulet (PODD) Receives a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on CH:GOV
Stifel Nicolaus
Stifel Nicolaus
CHF203.75CHF183.38
Buy
Assigned
07/10/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Insulet (NASDAQ: PODD)
Citi
CHF134.48CHF140.18
Hold
Reiterated
07/08/26
Citi Sticks to Their Hold Rating for Insulet (PODD)
Evercore ISI
CHF163CHF146.7
Buy
Reiterated
07/06/26
Insulet price target lowered to $180 from $200 at Evercore ISIInsulet price target lowered to $180 from $200 at Evercore ISI
Bank of America Securities Analyst forecast on CH:GOV
Bank of America Securities
Bank of America Securities
CHF169.52
Buy
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE) and Insulet (NASDAQ: PODD)
Piper Sandler Analyst forecast on CH:GOV
Piper Sandler
Piper Sandler
CHF171.15
Buy
Reiterated
06/15/26
Piper Sandler Keeps Their Buy Rating on Insulet (PODD)
BTIG
CHF191.53
Buy
Reiterated
06/15/26
BTIG Remains a Buy on Insulet (PODD)
Raymond James Analyst forecast on CH:GOV
Raymond James
Raymond James
CHF214.35CHF176.04
Buy
Reiterated
06/08/26
Raymond James Sticks to Their Buy Rating for Insulet (PODD)
Wells Fargo Analyst forecast on CH:GOV
Wells Fargo
Wells Fargo
CHF207.83
Buy
Reiterated
06/08/26
Wells Fargo Reaffirms Their Buy Rating on Insulet (PODD)
William Blair Analyst forecast on CH:GOV
William Blair
William Blair
Buy
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)
Barclays Analyst forecast on CH:GOV
Barclays
Barclays
CHF161.37
Sell
Reiterated
05/28/26
Insulet (PODD) Receives a Sell from Barclays
Goldman Sachs Analyst forecast on CH:GOV
Goldman Sachs
Goldman Sachs
CHF193.16CHF167.08
Buy
Reiterated
05/27/26
Insulet price target lowered to $205 from $237 at Goldman SachsInsulet price target lowered to $205 from $237 at Goldman Sachs
Benchmark Co. Analyst forecast on CH:GOV
Benchmark Co.
Benchmark Co.
CHF203.75
Buy
Initiated
05/12/26
Insulet initiated with a Buy at BenchmarkInsulet initiated with a Buy at Benchmark
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
CHF141.81
Hold
Downgraded
07/28/26
Insulet assumed with Neutral from Buy at UBSInsulet assumed with Neutral from Buy at UBS
Truist Financial Analyst forecast on CH:GOV
Truist Financial
Truist Financial
CHF178.49CHF171.15
Buy
Reiterated
07/13/26
Insulet price target lowered to $210 from $219 at TruistInsulet price target lowered to $210 from $219 at Truist
RBC Capital
CHF228.2CHF199.68
Buy
Reiterated
07/13/26
Insulet (PODD) Receives a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on CH:GOV
Stifel Nicolaus
Stifel Nicolaus
CHF203.75CHF183.38
Buy
Assigned
07/10/26
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Insulet (NASDAQ: PODD)
Citi
CHF134.48CHF140.18
Hold
Reiterated
07/08/26
Citi Sticks to Their Hold Rating for Insulet (PODD)
Evercore ISI
CHF163CHF146.7
Buy
Reiterated
07/06/26
Insulet price target lowered to $180 from $200 at Evercore ISIInsulet price target lowered to $180 from $200 at Evercore ISI
Bank of America Securities Analyst forecast on CH:GOV
Bank of America Securities
Bank of America Securities
CHF169.52
Buy
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE) and Insulet (NASDAQ: PODD)
Piper Sandler Analyst forecast on CH:GOV
Piper Sandler
Piper Sandler
CHF171.15
Buy
Reiterated
06/15/26
Piper Sandler Keeps Their Buy Rating on Insulet (PODD)
BTIG
CHF191.53
Buy
Reiterated
06/15/26
BTIG Remains a Buy on Insulet (PODD)
Raymond James Analyst forecast on CH:GOV
Raymond James
Raymond James
CHF214.35CHF176.04
Buy
Reiterated
06/08/26
Raymond James Sticks to Their Buy Rating for Insulet (PODD)
Wells Fargo Analyst forecast on CH:GOV
Wells Fargo
Wells Fargo
CHF207.83
Buy
Reiterated
06/08/26
Wells Fargo Reaffirms Their Buy Rating on Insulet (PODD)
William Blair Analyst forecast on CH:GOV
William Blair
William Blair
Buy
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)
Barclays Analyst forecast on CH:GOV
Barclays
Barclays
CHF161.37
Sell
Reiterated
05/28/26
Insulet (PODD) Receives a Sell from Barclays
Goldman Sachs Analyst forecast on CH:GOV
Goldman Sachs
Goldman Sachs
CHF193.16CHF167.08
Buy
Reiterated
05/27/26
Insulet price target lowered to $205 from $237 at Goldman SachsInsulet price target lowered to $205 from $237 at Goldman Sachs
Benchmark Co. Analyst forecast on CH:GOV
Benchmark Co.
Benchmark Co.
CHF203.75
Buy
Initiated
05/12/26
Insulet initiated with a Buy at BenchmarkInsulet initiated with a Buy at Benchmark
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insulet

3 Months
Success Rate
16/19 ratings generated profit
84%
Average Return
+9.54%
Copying Matthew Taylor's trades and holding each position for 3 Months would result in 84.21% of your transactions generating a profit, with an average return of +9.54% per trade.
1 Year
Suraj KaliaOppenheimer
Success Rate
12/14 ratings generated profit
86%
Average Return
+20.57%
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +20.57% per trade.
2 Years
Suraj KaliaOppenheimer
Success Rate
12/14 ratings generated profit
86%
Average Return
+35.33%
Copying Suraj Kalia's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +35.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GOV Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
8
12
20
20
16
Buy
20
17
15
21
21
Hold
2
3
5
5
5
Sell
2
1
2
2
2
Strong Sell
0
0
0
0
0
total
32
33
42
48
44
In the current month, GOV has received 37 Buy Ratings, 5 Hold Ratings, and 2 Sell Ratings. GOV average Analyst price target in the past 3 months is 181.71.
Each month's total comprises the sum of three months' worth of ratings.

GOV Financial Forecast

GOV Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

GOV Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

GOV Stock Forecast FAQ

What is CH:GOV’s average 12-month price target, according to analysts?
Based on analyst ratings, Insulet’s 12-month average price target is 181.71.
    What is CH:GOV’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:GOV, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Insulet a Buy, Sell or Hold?
        Insulet has a consensus rating of Strong Buy, which is based on 17 buy ratings, 3 hold ratings and 1 sell ratings.
          What is Insulet’s share price target?
          The average share price target for Insulet is 181.71. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF239.61 ,and the lowest forecast is CHF140.18. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Insulet?
            Insulet’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
              How can I buy shares of Insulet?
              To buy shares of CH:GOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.